Özofagus Skuamöz Hücreli Karsinomlarında Prognozun Belirlenmesinde D2-40 ve Cox-2 Ekspresyonunun Önemi

Giriş ve Amaç: Özofagus Skuamöz Hücreli Karsinomu (ÖSHK) dünyada maligniteler içerisinde sekizinci sırada görülmesine rağmen bulunduğumuz coğrafyada beşinci sırada yer almaktadır. Prognozu oldukça kötü olup beş yıllık sağ kalım oranı %16-20’dir. Surveyinin çok düşük olduğu göz önüne alınacak olursa prognozun belirlenmesi ve tedavinin şekillenmesinde kullanılabilecek yeni belirteçlere ihtiyaç vardır. Bu amaçla son yıllarda önem kazanmış olan COX-2 ve D2-40 belirteçlerinin ÖSHK’lardaki yeri araştırılıp sağ kalım ve prognostik parametrelerle ilişkisi belirlenmeye çalışılmıştır. Gereç ve Yöntemler: Çalışmamızda ÖSHK’da COX-2 ve D2-40 antikorlarıyla immünhistokimyasal boyama uygulanarak boyanmanın yaygınlığı, yoğunluğu, histoskorları ile prognostik parametreler ve sağ kalım arasındaki ilişki istatistiksel olarak değerlendirildi. Bulgular: COX-2 ile invazyon derinliği, lenfovasküler invazyon, lenf nodu metastazı, klinik evre ve sağ kalım; D2- 40 ile klinik evre, lenfovasküler invazyon ve lenf nodu metastazı arasında anlamlı ilişki tespit edildi. Sonuç: Sonuç olarak her iki belirteç de (D2-40 ve COX-2) ÖSHK’da prognozu belirlemede anlamlı bulundu.

Importance of D2-40 and Cox-2 Expression in Determination of the Prognosis in Esophageal Squamous Cell Carcinomas

Objective: Esophageal squamous cell carcinoma (ESCC) is the eighth most common cancer type in worldwide whereas it has the fifth rank in our region. Prognosis is poor, and survival rate lies between 16-20% after five years. Considering the low survival, new biomarkers are needed for planning the therapy and the estimation of the prognosis. Materials and Methods: Potential role of COX-2 and D2-40 is investigated in ESCC and their associations with survival and prognostic parameters are sought. Results: COX-2 staining was found to be associated with invasion depth, lymphovascular invasion, lymph node metastasis, tumor stage and survival whereas D2-40 was found to be associated with lymphovascular invasion, lymph node metastasis and tumor stage. Conclusion: As a conclusion (COX-2, D2-40), both markers were found useful in the estimation of prognosis of ESCC.

Kaynakça

1. Zhang, Y, Epidemiology of esophageal cancer. World Journal of Gastroenterology, 2013, 19(34), 5598-5606.

2. Şengül, A.T, Özofagus kanserinin epidemiyolojisi, Journal of Experimental and Clinical Medicine 2012, 203-208.

3. Matsui, K, Breitender-Geleff, S ve ark, Podoplanin, a novel 43-kDa membrane protein, controls the shape of podocytes, Nephrology Dialysis Transplant, 1999, 1, 9–11.

4. Tong, L, Yuan, S, Feng, F, Zhang, H, Role of podoplanin expression in esophageal squamous cell carcinoma: a retrospective study, Diseases of the Esophagus, 2012, 25, 72–80.

5. Ma, W, Wang, K ve ark, Clinicopathology significance of podoplanin immunoreactivity in esophageal squamous cell carcinoma, International Journal of Clinical and Experimental Pathology, 2014, 7(5), 2361-2371.

6. Bai, B, Ma, W ve ark, Detection of D2-40 monoclonal antibodylabeled lymphatic vessel invasion in esophageal squamous cell carcinoma and its clinicopathologic significance, Cancer Biology Medicine, 2013, 10(2), 81-85.

7. Gridley, G, McLaughlin, JK ve ark, İncidence of cancer among patients with rheumatoid arthiritis, Journal of the National Cancer Institute, 1993, 85 (4), 307-311.

8. IARC Handbooks on Cancer Prevention, volüme 1, Non-steroidal antiinflamatory drugs, IARC Scientific Publication. Lyon, France, 1997.

9. Zhi, H, Wang, L, Zhang, J, Zhou, C, Ding, F, Luo, A, Wu, M, Zhan, Q, Liu, Z, Significance of COX-2 expression in human esophageal squamous cell carcinoma, Carcinogenesis, 2006, 27, 1214–1221.

10. Akutsu, Y, Hanari, N, Yusup, G, Komatsu-Akimoto, A, Ikeda, N, Mori, M, Yoneyama, Y, Endo, S, Miyazawa, Y, Matsubara, H, COX2 Expression Predicts Resistance to Chemoradiotherapy in Esophageal Squamous Cell Carcinoma, Annals of Surgical Oncology, 2011, 18, 2946–2951.

11. Williams, CS, Mann, M, DuBois, RN, The role of cyclooxygenases in inflammation, cancer, and development, Oncogene, 1999, 18, 7908- 7916.

12. Wang, F, Duan, H, Cai, M, Fu, J, Ma, G, Yang, H, Prognostic Significance of the pN Classification Supplemented by Vascular Invasion for Esophageal Squamous Cell Carcinoma, Thoracic Cancer, 2015, 6(6), 765–771.

13. Sjoquist, KM, Burmeister, BH, Smithers, BM, Zalcberg, JR, Simes, RJ, Barbour, A, Gebski, V, Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis, Lancet Oncology, 2011, 12(7), 681-92.

14. Oesophageal Cancer Estimated Incidence, Mortality and Prevalence Worldwide in 2012, http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx

15. Boran, M, Göl, H, Özofagus Kanserinde Epidemiyoloji, Turkiye Klinikleri Dergisi, 2007, 3(29), 1-4.

16. Kutlay, H, Cangır, AK, Ökten, İ, Özofagus kanserlerinde epidemiyoloji ve risk faktörleri, Türkiye Klinikleri Cerrahi Dergisi, 2000, 5,1-3.

17. Liu, R, Xu, KP, Tan, GS, Cyclooxygenase-2 inhibitors in lung cancer treatment: Bench to bed, European Journal of Pharmacology, 2015, 769, 127-33.

18. Altorki, N, COX-2: a target for prevention and treatment of esophageal cancer, Journal of Surgical Research, 2004, 117, 114–20.

19. Huang, JX, Xiao, W ve ark, Relationship between COX-2 and cell cycle-regulatory proteins in patients with esophageal squamous cell carcinoma, World Journal Gastroenterology, 2010, 16(47), 5975- 5981.

20. Takatori, H, Natsugoe, S ve ark, Cyclooxygenase-2 expression is related to prognosis in patients with esophageal squamous cell carcinoma, Europian Journal Surgical Oncology, 2008, 34(4), 397- 402.

21. Nozoe, T, Ezaki, T ve ark, Significance of immunohistochemical expression of cyclooxygenase-2 in squamous cell carcinoma of the esophagus, The American Journal of Surgery, 2005, 189, 110–115.

22. Masferrer, JL, Leahy, KM ve ark, Antiangiogenic and Antitumor Activities of Cyclooxygenase-2 Inhibitors, Cancer Research, 2000, 60(5), 1306-11.

23. Taketo, MM, Cyclooxygenase-2 Inhibitors in Tumorigenesis (Part II), Journal of the National Cancer Institute, 1998, 90, 1609–20.

24. Xi, H, Baldus, SE ve ark, High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer, Clinical Cancer Research, 2005, 11(23), 8341-7.

25. Cao, Y, Prescott, SM, Many actions of cyclooxygenase-2 in cellular dynamics and in cancer, Journal of Cellular Physiology, 2002, 190(3), 279-86.

26. Sobolewski, C, Cerella, C, Dicato, M, Ghibelli, L, Diederich, M, The Role of Cyclooxygenase-2 in Cell Proliferation and Cell Death in Human Malignancies, Hindawi Publishing Corporation, International Journal of Cell Biology, 2010, 21.

27. Schacht, V, Dadras, SS, Johnson, LA, Up-Regulation of the Lymphatic Marker Podoplanin, a Mucin-Type Transmembrane Glycoprotein, in Human Squamous Cell Carcinomas and Germ Cell Tumors, American Journal of Pathology, 2005, 166(3), 913-921.

28. Atsumi, N, Ishii, G, Kojima, M, Sanada, M, Fujii, S, Ochiai, A, Podoplanin, a novel marker of tumor-initiating cells in human squamous cell carcinoma A431, Biochemical and Biophysical Research Communications, 2008, 373, 36–41.

29. Rahadiani, N, Ikeda, J, Makino, T, Tian, T, Qiu, Y, Mamat S, Wang, Y, Doki, Y, Aozasa, K, Morii, E, Tumorigenic Role of Podoplanin in Esophageal Squamous-Cell Carcinoma. Annals of Surgical Oncology, 2010, 17, 1311–1323.

30. Toll, A, Gimeno, J, Ferrandiz C, D2-40 immunohistochemical overexpression in cutaneous squamous cell carcinomas: A marker of metastatic risk, Journal of the American Academy of Dermatology, 2012, 67, 1310-1318.

31. Chen, B, Fang, WK ve ark, The prognostic implications of microvascular density and lymphatic vessel density in esophageal squamous cell carcinoma: Comparative analysis between the traditional whole sections and the tissue microarray, Acta Histochemica, 2014, 116(4), 646-53.

32. Imamura, Y, Watanabe, M ve ark, Lymphatic Vessel Invasion Detected by the D2-40 Monoclonal Antibody Is an Independent Prognostic Factor in Node-Negative Esophageal Squamous Cell Carcinoma, Journal of Surgical Oncology, 2012, 105, 277–283.

33. Prasad, B, Kashyap, B, Babu, GS, Kumar, GR, Manyam, R, Expression of Podoplanin in Different Grades of Oral Squamous Cell Carcinoma, Annals of Medical And Health Science Research, 2015, 5(4), 299-304.

34. Prince, ME, Sivanandan, R ve ark, Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma, Proceedings of the National Academy of Sciences, 2007, 104(3), 973-978.

Kaynak Göster